The Axonal Transport Dysfunction Hypothesis proposes that impaired bidirectional transport of cargo along microtubules in dopaminergic neurons is an upstream driver of neurodegeneration in Parkinson's Disease. This dysfunction disrupts mitochondrial positioning, synaptic vesicle delivery, protein homeostasis, and lysosomal trafficking—creating a cascade of cellular failures that culminate in neuronal death.
Axonal transport relies on the microtubule cytoskeleton and molecular motors:
| Component | Function | PD Relevance |
|---|---|---|
| Kinesin-1/2/3 | Anterograde transport (soma → synapse) | Delivers mitochondria, synaptic vesicles, proteins |
| Dynein-dynactin | Retrograde transport (synapse → soma) | Returns signaling endosomes, damaged cargo |
| Microtubules | Track for motor proteins | Tau hyperphosphorylation disrupts tracks |
| Miro1/Miro2 | Mitochondrial anchoring proteins | Mutations cause parkinsonism |
| Milton/Trafficking proteins | Kinesin adaptors for mitochondria | Regulate mitochondrial distribution |
A. Microtubule Disruption
B. Motor Protein Dysfunction
C. Mitochondrial Transport Failure
D. Vesicle Trafficking Impairment
| Consequence | Mechanism | Outcome |
|---|---|---|
| Energy deficit | Mitochondria fail to reach synaptic terminals | Synaptic failure |
| Protein accumulation | Autophagosomes/lysosomes not delivered | Protein aggregates |
| Axonal degeneration | Distal segments lose support | Neurite shortening |
| Synaptic loss | Vesicle delivery failure | Early motor symptoms |
| Retrograde signaling failure | Dynein-mediated signaling impaired | Loss of trophic support |
| Pathway | Connection to Axonal Transport |
|---|---|
| Alpha-synuclein aggregation | Oligomers impair motor function; transport deficits increase aggregation susceptibility |
| Mitochondrial dysfunction | Bidirectional relationship—energy failure impairs transport; transport failure worsens mitochondrial distribution |
| LRRK2 pathogenesis | LRRK2 phosphorylates microtubule-associated proteins and transport regulators |
| Neuroinflammation | Transport defects impair lysosomal delivery to distal processes |
Rationale: Moderate evidence from genetic, post-mortem, and model system studies. High therapeutic potential with multiple druggable targets. Key gap is causal direction—transport dysfunction may be upstream driver or downstream consequence.
Why Novel: Positions axonal transport as primary upstream event rather than secondary manifestation. Connects disparate genetic causes (LRRK2, GBA, VPS35, DYNC1H1) through common transport pathway impairment.
Last updated: 2026-04-01
Related: Axonal Transport Defects, Synaptic Vesicle Trafficking, Mitochondrial Dynamics